{"id":"vli","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Neutropenia"},{"rate":"20-30","effect":"Peripheral neuropathy"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-20","effect":"Nausea and vomiting"},{"rate":"15-25","effect":"Constipation"},{"rate":"10-15","effect":"Alopecia"}]},"_chembl":null,"_dailymed":{"setId":"35a7873a-e340-aae3-e063-6294a90a767f","title":"VLITEPRO FIRST AID WIPES (ISOPROPYL ALCOHOL CLOTH) CLOTH [YIWU ORI-POWER MEDTECH CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Vinca alkaloids like VLI bind to β-tubulin and prevent microtubule polymerization, which disrupts the mitotic spindle formation necessary for cell division. This leads to metaphase arrest and apoptosis in cancer cells. The drug is particularly effective against rapidly dividing cells with high mitotic activity.","oneSentence":"VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:27:29.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Non-Hodgkin lymphoma"},{"name":"Acute lymphoblastic leukemia"},{"name":"Breast cancer"},{"name":"Lung cancer"},{"name":"Testicular cancer"}]},"trialDetails":[{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT02925000","phase":"PHASE1, PHASE2","title":"Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2017-06-19","conditions":"Cancer","enrollment":46},{"nctId":"NCT02697305","phase":"NA","title":"Incretin Effects of Branched Chain Amino Acids","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2014-09","conditions":"Glucose Metabolism Disorders","enrollment":18},{"nctId":"NCT00364676","phase":"PHASE1","title":"Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","startDate":"2006-07","conditions":"Tumors, Hodgkins Disease, Non-Hodgkins Lymphoma","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":114,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VLI","genericName":"VLI","companyName":"Spectrum Pharmaceuticals, Inc","companyId":"spectrum-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells. Used for Hodgkin lymphoma, Non-Hodgkin lymphoma, Acute lymphoblastic leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}